ATH 0.00% 0.3¢ alterity therapeutics limited

Paper Alert: Aducanumab Phase 1b Study Published, page-12

  1. 516 Posts.
    lightbulb Created with Sketch. 13
    One thing is for sure Mr market never responded to posters like you no matter how hard you were promoting the company or blaming FDA. All the efforts were futile. it is beyond your knowledge.
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.